









Markets
/
Stocks
/
nasdaq-zntl
/

Zentalis Pharmaceuticals Inc

ZNTL

View Detailed Chart

1.340USD

-0.040-2.90%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

96.41MMarket Cap

LossP/E TTM



Zentalis Pharmaceuticals Inc

1.340

-0.040-2.90%

Overview Company Financials

Financials

Intraday

30m

Today

-2.90%

5 Days

-8.84%

1 Month

+6.35%

6 Months

-20.24%

Year to Date

-55.78%

1 Year

-62.88%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 9 analysts

BUY

Current Rating

6.071

Target Price

353.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Zentalis Pharmaceuticals Inc

ZNTL

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(10)

Neutral(2)

Buy(0)

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.014

Neutral

RSI(14)

46.904

Neutral

STOCH(KDJ)(9,3,3)

20.045

Sell

ATR(14)

0.080

Low Volatility

CCI(14)

-128.939

Sell

Williams %R

78.261

Sell

TRIX(12,20)

0.330

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.378

Sell

MA10

1.416

Sell

MA20

1.379

Sell

MA50

1.352

Sell

MA100

1.404

Sell

MA200

2.118

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Ticker SymbolZNTL

CompanyZentalis Pharmaceuticals Inc

CEOMs. Julie Eastland

Websitehttps://www.zentalis.com/